Sol-Gel Technologies (NASDAQ:SLGL) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Sol-Gel Technologies (NASDAQ:SLGL) from a buy rating to a hold rating in a research note published on Saturday morning.

SLGL has been the subject of a number of other research reports. Zacks Research upgraded Sol-Gel Technologies to a “hold” rating in a report on Tuesday, October 28th. HC Wainwright lifted their target price on Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Sol-Gel Technologies has an average rating of “Hold” and an average target price of $50.00.

Sol-Gel Technologies Price Performance

NASDAQ:SLGL opened at $35.54 on Friday. The company has a market cap of $99.01 million, a price-to-earnings ratio of -28.89 and a beta of 1.29. The stock’s 50 day simple moving average is $31.54 and its two-hundred day simple moving average is $17.04. Sol-Gel Technologies has a 1 year low of $4.01 and a 1 year high of $52.26.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its earnings results on Friday, August 15th. The company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $4.84. The firm had revenue of $17.26 million during the quarter, compared to analysts’ expectations of $2.86 million. Sol-Gel Technologies had a negative return on equity of 11.80% and a negative net margin of 14.25%. As a group, analysts anticipate that Sol-Gel Technologies will post -0.28 EPS for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.